Fact-checked by Grok 2 weeks ago

Antidiuretic

An antidiuretic is a substance that reduces urination to help control fluid balance in the body by opposing diuresis. The primary natural antidiuretic is antidiuretic hormone (ADH), also known as arginine vasopressin (AVP), a nonapeptide hormone synthesized in the hypothalamus and released from the posterior pituitary gland that primarily regulates water retention by the kidneys to maintain osmotic balance and blood volume.^[1] ADH acts on the collecting ducts of the nephron, increasing their permeability to water through the insertion of aquaporin-2 channels into the apical membrane of principal cells, thereby reducing urine output and concentrating urine.^[2] Its release is primarily stimulated by increased plasma osmolality detected by osmoreceptors in the hypothalamus or by decreased blood volume sensed by baroreceptors, with sensitivity to osmolality changes as small as 2 mOsm/L.^[1] In addition to its antidiuretic effects, ADH exerts vasoconstrictive actions at higher concentrations by binding to V1 receptors on vascular smooth muscle, helping to elevate blood pressure during hypovolemia.^[2] Dysregulation of ADH can lead to conditions such as syndrome of inappropriate antidiuretic hormone secretion (SIADH), causing hyponatremia, or diabetes insipidus, characterized by excessive urination due to ADH deficiency or renal resistance.^[1] Synthetic antidiuretics, such as desmopressin, mimic ADH's effects and are used therapeutically.^[1]

Definition and Types

Definition

An antidiuretic is any substance or hormone that inhibits diuresis, the production of urine, by promoting the reabsorption of water in the kidneys, resulting in the formation of concentrated urine and a reduction in overall urine volume.^[1] This action helps conserve body water and maintain osmotic balance.^[1] The primary example of an antidiuretic is antidiuretic hormone (ADH), also known as vasopressin, a peptide hormone consisting of nine amino acids that is synthesized in the supraoptic and paraventricular nuclei of the hypothalamus and subsequently released from the posterior pituitary gland into the bloodstream.^[1] The term "antidiuretic" was coined in the early 20th century to describe the effects of pituitary extracts that opposed diuresis, following observations in 1913 by researchers such as Arturo Farini and Richard von den Velden, who demonstrated the antidiuretic properties of these extracts in treating diabetes insipidus.^[3] Through its antidiuretic effects, ADH plays a fundamental role in maintaining body fluid homeostasis by counteracting dehydration and regulating plasma osmolality, ensuring that water is retained when bodily needs demand it.^[1]

Natural and Synthetic Antidiuretics

Natural antidiuretics primarily encompass endogenous peptide hormones that regulate water balance by promoting renal water reabsorption. The principal natural antidiuretic is arginine vasopressin (AVP), also known as antidiuretic hormone (ADH), a nonapeptide hormone synthesized in the hypothalamus and consisting of nine amino acids with a characteristic disulfide bridge forming a cyclic structure.^[1]^[4] In humans, AVP binds to vasopressin V2 receptors to exert its antidiuretic effects, distinguishing it from its vasoconstrictive actions mediated by V1 receptors.^[5] Oxytocin, another hypothalamic nonapeptide structurally similar to AVP, differing at amino acid positions 3 and 8, exhibits minor antidiuretic activity at high concentrations, primarily through cross-activation of V2 receptors, though its primary roles involve uterine contraction and milk ejection.^[6]^[7] Synthetic antidiuretics are engineered analogs of natural vasopressin designed to enhance specificity, duration of action, and resistance to enzymatic degradation. Desmopressin (1-deamino-8-D-arginine vasopressin, or DDAVP) is a prominent example, modified from AVP by removal of the N-terminal amino group (deamination) and substitution of L-arginine with D-arginine at position 8, resulting in a longer plasma half-life of 90–190 minutes compared to AVP's shorter duration and increased selectivity for V2 receptors over V1.^[5]^[8] This structural alteration minimizes vasoconstrictive side effects while preserving antidiuretic potency, making desmopressin suitable for conditions requiring targeted water retention.^[9] Terlipressin, or triglycyl-lysine vasopressin, represents another synthetic variant where three glycine residues are added to the N-terminus of lysine vasopressin, conferring prodrug-like properties that slowly release active vasopressin; it demonstrates dose-dependent antidiuretic effects at low doses (0.05–1.0 μg/kg) alongside its primary vasoconstrictive applications.^[10]^[11] While hormone-based agents dominate antidiuretic pharmacology, non-hormonal examples include certain prostaglandin inhibitors and antagonists of atrial natriuretic peptide (ANP), which indirectly enhance water retention by counteracting natriuretic and diuretic pathways.^[12] However, these are less commonly emphasized compared to vasopressin derivatives due to their broader physiological impacts and limited clinical specificity for antidiuresis.^[13]

Physiological Mechanisms

Role of Antidiuretic Hormone (ADH)

Antidiuretic hormone (ADH), also known as arginine vasopressin (AVP), is synthesized in the magnocellular neurons of the supraoptic and paraventricular nuclei within the hypothalamus. It is initially produced as a larger precursor protein called preprovasopressin, which consists of 164 amino acids and includes a signal peptide, the mature AVP nonapeptide, neurophysin II, and a glycopeptide known as copeptin. During transport along the axonal projections to the posterior pituitary, the precursor undergoes enzymatic processing in the Golgi apparatus and secretory granules, cleaving it into the active 9-amino-acid hormone ADH, along with neurophysin II and copeptin, which are released in equimolar ratios.^[14]^[15] Once synthesized, ADH is packaged into secretory granules and transported via the hypothalamo-neurohypophyseal tract to the posterior pituitary gland, where it is stored until release into the systemic circulation. Release occurs in response to physiological stimuli, such as increased plasma osmolality detected by hypothalamic osmoreceptors, leading to pulsatile secretion that maintains water balance. In circulation, ADH has a short half-life of approximately 10-20 minutes, primarily due to rapid metabolism by vasopressinases in the liver and kidneys, as well as renal excretion.^[1]^[16]^[17] ADH exerts its primary antidiuretic effects by binding to V2 receptors, which are G-protein-coupled receptors predominantly expressed on the basolateral membrane of principal cells in the kidney's collecting ducts, promoting water reabsorption to concentrate urine. It also interacts with V1 receptors, particularly the V1a subtype on vascular smooth muscle cells, inducing vasoconstriction at higher concentrations to support blood pressure regulation. Additionally, through V1b (or V3) receptors in the anterior pituitary, ADH stimulates adrenocorticotropic hormone (ACTH) release, contributing to stress responses, though these non-renal actions are secondary to its central role in osmoregulation.^[1]^[18]^[19]

Action in the Kidney

Antidiuretic hormone (ADH), also known as vasopressin, primarily targets the collecting ducts of the nephron in the kidney, where it enhances water permeability to facilitate reabsorption. In the absence of ADH, the collecting ducts remain relatively impermeable to water, allowing dilute urine to be excreted. Upon binding to ADH, the epithelial cells lining these ducts undergo a series of intracellular changes that insert water channels into the membrane, enabling the kidney to conserve water and produce concentrated urine. This action is crucial for maintaining body fluid homeostasis by preventing excessive water loss. At the molecular level, ADH exerts its effects by binding to vasopressin V2 receptors (V2R) on the basolateral membrane of principal cells in the collecting ducts. This binding activates the G-protein-coupled receptor, which stimulates adenylate cyclase to increase intracellular cyclic adenosine monophosphate (cAMP) levels. Elevated cAMP then activates protein kinase A (PKA), leading to the phosphorylation of regulatory proteins that promote the trafficking and insertion of aquaporin-2 (AQP2) water channels from intracellular vesicles into the apical membrane facing the tubular lumen. AQP2 channels allow water to move passively down its osmotic gradient from the urine into the cell, where it can then exit via basolateral aquaporin-3 and -4 channels into the bloodstream. This regulated insertion of AQP2 is a rapid process, occurring within minutes of ADH stimulation, and is reversible upon hormone withdrawal. The water reabsorption process in the collecting ducts relies on an osmotic gradient established earlier in the nephron by the countercurrent multiplier system in the loop of Henle. The descending limb of the loop is permeable to water, which exits due to the hypertonic medullary interstitium, while the ascending limb actively transports ions out, creating a progressively increasing osmolarity in the medulla up to 1200 mOsm/L. This hypertonicity draws water from the collecting ducts through AQP2 channels under ADH influence, concentrating the urine and minimizing water excretion. Without this gradient, even with increased permeability, effective reabsorption would be impaired. In quantitative terms, ADH action can dramatically alter urine output; in its absence, the kidneys may produce up to 20 liters of dilute urine per day, whereas maximal ADH stimulation reduces this to less than 1 liter of highly concentrated urine, demonstrating the hormone's pivotal role in water conservation. This capacity underscores the efficiency of the renal response in adapting to varying hydration states.

Regulation of Antidiuretic Activity

Osmotic Regulation

Osmoreceptors responsible for the osmotic regulation of antidiuretic hormone (ADH), also known as vasopressin, are located in the anterior hypothalamus, particularly within the organum vasculosum of the lamina terminalis (OVLT). These specialized neurons detect subtle changes in plasma osmolality, with sensitivity to increases as small as 1-2 mOsm/kg above the normal range of 280-295 mOsm/kg.^[20] The OVLT lacks a complete blood-brain barrier, allowing direct exposure to circulating solutes and enabling rapid osmotic sensing.^[21] The threshold for ADH secretion is approximately 285 mOsm/kg, beyond which plasma ADH levels rise linearly with increasing osmolality, ensuring precise control of water balance.^[1] This linear relationship allows for graded responses: minor elevations in osmolality trigger modest ADH release, while larger increases provoke stronger secretion to restore homeostasis.^[22] Sodium ions primarily drive this osmotic signal due to their dominant contribution to extracellular osmolality, though other solutes like urea and glucose can also influence osmoreceptor activity when their concentrations fluctuate significantly.^[23] In the osmotic feedback loop, dehydration elevates plasma osmolality, activating OVLT osmoreceptors that project to the supraoptic and paraventricular nuclei in the hypothalamus. This stimulation prompts ADH release from the posterior pituitary, which acts on the renal collecting ducts to enhance water reabsorption via aquaporin-2 channels, thereby diluting the plasma and suppressing further ADH secretion.^[1] This negative feedback mechanism maintains plasma osmolality within narrow limits, preventing both hyperosmolar and hypoosmolar states.^[24]

Non-Osmotic Regulation

Non-osmotic regulation of antidiuretic hormone (ADH), also known as vasopressin, involves mechanisms that stimulate its release independently of plasma osmolality changes, primarily in response to alterations in effective circulating volume or other physiological stressors.^[1] These pathways allow the body to prioritize volume conservation during conditions like hypovolemia, overriding the primary osmotic control that maintains plasma tonicity.^[24] Baroreceptors located in the aortic arch, carotid sinus, and left atrium play a central role in detecting reductions in blood volume or pressure. During hypovolemia, such as in hemorrhage, these baroreceptors exhibit decreased firing rates, which are transmitted via afferent vagal and glossopharyngeal nerves to the brainstem and subsequently to the hypothalamus, stimulating ADH release from the posterior pituitary.^[1] This response promotes renal water reabsorption and vasoconstriction to restore hemodynamic stability.^[24] Additional neural inputs further modulate ADH secretion through non-osmotic means. Angiotensin II, generated by the renin-angiotensin-aldosterone system in response to hypovolemia, directly stimulates hypothalamic neurons to potentiate ADH release.^[1] Similarly, stimuli such as nausea, pain, and various forms of stress activate hypothalamic pathways, including the emetic reflex and central catecholaminergic systems, leading to increased ADH secretion.^[24] Non-osmotic stimuli typically require a substantial volume deficit, such as greater than 10% loss of effective circulating volume, to significantly override the dominant osmotic regulation threshold.^[1] This ensures that osmoregulation remains the baseline control under normal conditions, with volume-sensitive mechanisms activating only during severe perturbations.^[25] Clinically, these non-osmotic pathways contribute to hyponatremia in scenarios involving acute volume depletion or postoperative states, where pain, nausea, or surgical stress triggers excessive ADH release, impairing free water excretion despite normal or low osmolality.^[1]

Pathophysiological Implications

Deficiency States

Deficiency states of antidiuretic activity primarily manifest as diabetes insipidus, a group of disorders characterized by the inability to concentrate urine due to insufficient antidiuretic hormone (ADH) action, leading to excessive water loss.^[26] These conditions result in polyuria exceeding 3 liters per day, often up to 20 liters in severe cases, and are rare, affecting approximately 1 in 25,000 individuals worldwide.^[27] The primary forms include central diabetes insipidus, nephrogenic diabetes insipidus, and gestational diabetes insipidus during pregnancy.^[26] Central diabetes insipidus arises from ADH deficiency due to damage or dysfunction of the hypothalamus or posterior pituitary gland, such as from head trauma, tumors, infections, or neurosurgical interventions.^[26] This leads to reduced or absent ADH secretion, impairing water reabsorption in the renal collecting ducts and causing dilute urine output despite dehydration.^[27] In severe cases, patients may experience polyuria of up to 20 liters per day, accompanied by intense thirst.^[26] Nephrogenic diabetes insipidus results from renal resistance to ADH, where the kidneys fail to respond appropriately even in the presence of elevated ADH levels, leading to persistently low urine osmolality below 300 mOsm/kg.^[27] Common causes include genetic mutations in the vasopressin V2 receptor gene (AVPR2) on the X chromosome, accounting for about 90% of congenital cases, or acquired factors such as lithium toxicity and chronic hypercalcemia.^[28] This form can be complete, with no urine concentration ability, or partial, allowing some response to ADH and milder polyuria.^[28] Across these deficiency states, core symptoms include polydipsia with a preference for cold water, recurrent dehydration, and hypernatremia if fluid intake is inadequate, potentially progressing to confusion, seizures, or coma in untreated cases.^[26] Gestational diabetes insipidus, a transient form unique to pregnancy, occurs in 2 to 4 per 100,000 pregnancies due to increased placental vasopressinase enzyme activity that degrades ADH, typically resolving postpartum.^[29]

Excess States

Excess states of antidiuretic hormone (ADH) activity, also known as antidiuretic excess, occur when there is inappropriate or excessive secretion of ADH, leading to impaired water excretion, water retention, and dilutional hyponatremia. This condition disrupts the normal balance of fluid and electrolytes, resulting in low serum sodium levels despite normal total body sodium, often presenting as euvolemic hyponatremia. The hallmark is continued ADH action that is not suppressed by low plasma osmolality, causing the kidneys to reabsorb excessive water independently of osmotic needs.^[30] The syndrome of inappropriate ADH secretion (SIADH) represents the prototypical excess state, characterized by unsuppressed ADH release from the posterior pituitary or ectopic sources, leading to hyponatremia with inappropriately concentrated urine. Ectopic ADH production commonly arises from malignancies, particularly small cell lung cancer (SCLC), which accounts for up to 70% of tumor-related cases, as tumor cells autonomously synthesize and release ADH. Central nervous system (CNS) disorders, such as stroke, subarachnoid hemorrhage, infections, trauma, or brain tumors, can also trigger SIADH by disrupting regulatory pathways in the hypothalamus or pituitary. Diagnostic criteria for SIADH include serum sodium below 135 mEq/L, serum osmolality less than 275 mOsm/kg, urine osmolality greater than 100 mOsm/kg, and urine sodium exceeding 40 mEq/L in the setting of euvolemia.^[30]^[31] Beyond SIADH, other causes contribute to antidiuretic excess, including pharmacological agents that either stimulate ADH release or enhance its renal effects. Selective serotonin reuptake inhibitors (SSRIs) and carbamazepine are notable examples, with SSRIs promoting ADH secretion via serotonin-mediated pathways and carbamazepine increasing renal sensitivity to ADH. Hypothyroidism can mimic or precipitate SIADH through reduced cardiac output and altered osmoregulation, often resolving with thyroid hormone replacement. Postoperative states, particularly following major surgery, may induce transient ADH hypersecretion due to pain, nausea, or stress, leading to acute water retention.^[30]^[31] Symptoms of antidiuretic excess vary by acuity and severity of hyponatremia, stemming primarily from cerebral edema caused by hypo-osmolar swelling of brain cells. In acute forms (developing over less than 48 hours), severe hyponatremia (serum sodium <125 mEq/L) can manifest as headache, nausea, vomiting, confusion, and potentially life-threatening seizures or coma due to rapid brain edema. Chronic excess states (>48 hours) allow for partial adaptation, presenting with subtler symptoms such as fatigue, gait instability, cognitive impairment, and increased risk of falls or osteoporosis from prolonged hypo-osmolality.^[30]^[31] Pathophysiologically, excessive ADH binds to V2 receptors in the renal collecting ducts, activating aquaporin-2 channels to enhance water reabsorption, which expands intravascular volume and dilutes serum sodium. This mild volume expansion suppresses the renin-angiotensin-aldosterone system, reducing sodium reabsorption in the proximal tubule and contributing to natriuresis. Consequently, serum uric acid levels are low due to increased renal clearance from the expanded effective circulating volume, further distinguishing excess states from other hyponatremic conditions.^[30]^[31]

Clinical and Therapeutic Applications

Diagnostic Approaches

Diagnostic approaches to assess antidiuretic function primarily involve laboratory measurements of antidiuretic hormone (ADH) levels, dynamic tests to evaluate renal concentrating ability and hormonal responses, and neuroimaging to identify structural abnormalities in the hypothalamic-pituitary axis. These methods help differentiate between central and nephrogenic forms of antidiuretic deficiency, as well as excess states like the syndrome of inappropriate antidiuretic hormone secretion (SIADH).^[32] Plasma ADH, also known as arginine vasopressin (AVP), is measured using radioimmunoassay (RIA) or enzyme-linked immunosorbent assay (ELISA) techniques, which detect concentrations as low as 0.5-1 pg/mL after sample extraction to account for the hormone's instability in plasma.^[33]^[34] Normal basal plasma ADH levels typically range from 1 to 5 pg/mL, though values can vary with hydration status and assay sensitivity; elevated levels may indicate SIADH, while low or undetectable levels suggest central diabetes insipidus (DI).^[35]^[36] The water deprivation test evaluates the kidney's ability to concentrate urine in response to ADH, confirming antidiuretic deficiency when urine osmolality fails to rise appropriately. In this protocol, fluid intake is restricted for up to 8-18 hours while monitoring body weight, plasma osmolality, and urine osmolality every 1-2 hours; dehydration is halted if body weight loss exceeds 3-5% or plasma sodium reaches 145-150 mmol/L to prevent severe hypernatremia. Healthy individuals achieve urine osmolality above 800 mOsm/kg, whereas values below 300 mOsm/kg after deprivation indicate DI; subsequent administration of desmopressin (a synthetic ADH analog) distinguishes central DI (urine osmolality increases >50%) from nephrogenic DI (minimal response).^[32]^[37] Magnetic resonance imaging (MRI) of the pituitary gland and hypothalamus is essential for identifying structural causes of antidiuretic dysfunction, such as lesions disrupting ADH synthesis or release in central DI. High-resolution T1-weighted MRI with gadolinium contrast reveals the posterior pituitary's normal "bright spot" hyperintensity due to ADH storage vesicles; its absence or ectopic location suggests central DI, while thickened or enhancing pituitary stalk or hypothalamic masses indicate infiltrative, neoplastic, or inflammatory etiologies like tumors or sarcoidosis.^[38]^[39]

Pharmacological Interventions

Pharmacological interventions targeting antidiuretic hormone (ADH) activity include synthetic analogues that mimic its renal effects to treat deficiency states and receptor antagonists that block V2 receptors to manage excess states. Desmopressin acetate, a selective V2 receptor agonist and synthetic analogue of ADH, is the cornerstone therapy for central diabetes insipidus, effectively reducing polyuria by enhancing water reabsorption in the collecting ducts. Intranasal administration is commonly used, with typical doses ranging from 10 to 40 mcg daily, divided into one to three applications, providing 8 to 20 hours of antidiuresis per dose. Oral tablets offer an alternative for long-term management, starting at 0.05 mg (50 mcg) twice daily and titrated up to 0.4 mg (400 mcg) three times daily based on urinary output and osmolality.^[40]^[41]^[42] Vasopressin (arginine vasopressin), the natural hormone, is employed primarily for its vasoconstrictive properties in acute esophageal variceal bleeding but also exerts antidiuretic effects that contribute to potential complications. Administered intravenously at an initial rate of 0.2 to 0.4 units per minute, with escalation to 0.8 units per minute if needed, it controls hemorrhage in up to 80% of cases initially, though its antidiuretic action can lead to unintended water retention.^[43] Vasopressin V2 receptor antagonists, or vaptans, inhibit antidiuretic activity to promote free water excretion in conditions like the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Tolvaptan, an oral selective V2 antagonist, is approved for euvolemic hyponatremia associated with SIADH, with dosing initiated at 15 mg once daily and adjusted in 15 mg increments to a maximum of 60 mg daily, guided by serum sodium monitoring to achieve gradual correction. Conivaptan, a dual V1a/V2 antagonist for intravenous use, addresses acute hyponatremia in hospitalized patients, featuring a 20 mg loading dose infused over 30 minutes followed by 20 to 40 mg per 24 hours for up to 4 days, effectively raising serum sodium by 4 to 6 mEq/L in the first 24 hours.^[44]^[45] Route of administration varies by clinical context: intranasal desmopressin is favored for outpatient management of central diabetes insipidus due to its convenience and bioavailability exceeding 10%, while intravenous routes are reserved for acute scenarios, such as vasopressin or conivaptan infusions during emergencies to ensure rapid onset and precise control.^[40]^[45] Side effects of ADH agonists like desmopressin and vasopressin include hyponatremia from excessive aquaporin-2 activation and water retention, occurring in up to 5% of patients and potentially leading to seizures if sodium falls below 125 mEq/L. Vaptans such as tolvaptan and conivaptan, conversely, frequently cause thirst (up to 16% incidence) and dry mouth (up to 13%) due to aquaresis, which increases urine volume by 3 to 5 liters daily and requires fluid intake guidance to avoid hypernatremia.^[46]^[47]

References

[1]
Physiology, Vasopressin - StatPearls - NCBI Bookshelf
Aug 14, 2023 · ADH is the primary hormone responsible for tonicity homeostasis. Hyperosmolar states most strongly trigger its release. ADH is stored in neurons ...
[2]
Antidiuretic Hormone - Synthesis - Action - TeachMePhysiology
Aug 22, 2023 · Antidiuretic hormone (ADH), also known as vasopressin, is a small peptide hormone which regulates the body's retention of water.
[3]
Diabetes Insipidus: Celebrating a Century of Vasopressin Therapy
In 1947, Williams and Henry (65) introduced the term “nephrogenic diabetes insipidus” for the congenital syndrome in their 7 patients (ages 1–53) whose ...Missing: coined | Show results with:coined
[4]
Arginine vasopressin: Direct and indirect action on metabolism - PMC
AVP is composed of 9 amino acids, Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly−CONH2, cross-linked with a Cys-Cys disulfide bond in a ring structure.
[5]
Vasopressin and Its Analogues: From Natural Hormones to ...
Human neurohormone vasopressin (AVP) is synthesized in overlapping regions in the hypothalamus. It is mainly known for its vasoconstricting abilities.
[6]
Molecular Mechanisms of Antidiuretic Effect of Oxytocin - PMC - NIH
We conclude that vasopressin V2 receptors mediate the antidiuretic effects of oxytocin, including increased expression and apical trafficking of AQP2, p-AQP2, ...
[7]
Oxytocin - StatPearls - NCBI Bookshelf - NIH
Feb 15, 2025 · If oxytocin is given in doses too large or too slowly for 24 hours, the medication can exhibit an antidiuretic effect, resulting in extreme ...
[8]
Potent antidiuretic agonists, deamino-vasopressin and ... - PubMed
Deamination of vasopressin (AVP) enhances its antidiuretic activity. Moreover, introduction of D-Arg8 instead of its L enantiomer in deamino-vasopressin ...
[9]
Desmopressin - StatPearls - NCBI Bookshelf - NIH
Jun 22, 2023 · Desmopressin is a drug that acts on the vasopressin receptors of the body. It has many relevant clinical uses, ranging from nocturnal enuresis to hemophilia.Missing: AVP | Show results with:AVP
[10]
Antidiuretic Activity of Terlipressin (Triglycyl-Lysine Vasopressin)
TP in low doses of 0.05-1.0 micrograms/kg exhibited typical dose-dependent antidiuretic effect. In the dose of 0.2 micrograms/kg, the dynamics of urine and ...
[11]
Terlipressin for the Prevention and Treatment of Renal Decline in ...
Sep 28, 2023 · Terlipressin: Mechanism of Action. Terlipressin possesses vasoconstrictive, antihemorrhagic, and antidiuretic properties. Terlipressin ...
[12]
ANP-induced signaling cascade and its implications in renal ...
ANP increases glomerular permeability and filtration rate and antagonizes the deleterious effects of the renin-angiotensin-aldosterone system activation.Missing: antagonists | Show results with:antagonists
[13]
Hormones of the Cardiovascular System - Endotext - NCBI Bookshelf
Feb 6, 2015 · Neurohormonal systems play a critical role in cardiovascular homeostasis as well cardiovascular pathophysiology and diseases such as congestive heart failure.
[14]
Figure 4. [Post-transcription processing of vasopressin and...]. - NCBI
The pre-pro-vasopressin is a peptide consisting of 164 amino acids. This pre-pro-hormone is then converted to pro-vasopressin after the removal of the signal ...
[15]
Antidiuretic Hormone and Serum Osmolarity Physiology and ...
Jul 31, 2019 · Evidence is accumulating that increased osmolarity, AVP, copeptin, and dehydration are all associated with worse outcomes in chronic disease states.Missing: non- | Show results with:non-
[16]
Vasopressin Release - an overview | ScienceDirect Topics
Once released into the circulation, vasopressin is metabolized rapidly by vasopressinases in the liver and kidney, and has a short half-life of 10–35 min.
[17]
Role of vasopressin in current anesthetic practice - PMC
May 26, 2017 · Its plasma half-life is 10–35 min, being rapidly metabolized by liver and kidney vasopressinases (35%) and excreted through the kidney (65%) [7] ...
[18]
Vasopressin Receptor - an overview | ScienceDirect Topics
V1 receptors are involved in vasoconstriction, V2 receptors facilitate water retention in renal tubules, and V3 receptors are associated with corticotropin ...Missing: antidiuresis | Show results with:antidiuresis
[19]
Vasopressin V1a and V1b Receptors: From Molecules to ...
Among the variety of AVP actions, it is certain that the antidiuretic properties mediated by V2 receptors are of physiological importance as they control renal ...
[20]
Physiology, Osmoreceptors - StatPearls - NCBI Bookshelf
May 1, 2023 · These receptors function by titrating the thirst of an individual as well as regulating the arginine vasopressin (AVP) release from the posterior pituitary.Cellular Level · Mechanism · Clinical Significance
[21]
Vasopressin and Osmoregulation: Older Than You Thought - PMC
The regulation of water balance (“osmoregulation”) is a complex mechanism in which neural and kidney responses adjust urinary concentration in response to ...
[22]
A Simplified Index of the Plasma Sodium Threshold for Arginine ...
The mean sodium and osmolality thresholds for arginine vasopressin secretion were calculated as 137 +/- 2 mEq/L and 285 +/- 15 mOsm/kg H(2)O.Missing: ADH | Show results with:ADH
[23]
Physiology, Osmoregulation and Excretion - StatPearls - NCBI - NIH
May 1, 2023 · ADH serves a primary function to increase solute-free water reabsorption in the nephrons (less water excretion) to bring down body fluid ...Introduction · Organ Systems Involved · Mechanism · Pathophysiology<|control11|><|separator|>
[24]
The physiology of vasopressin release and the pathogenesis of ...
The results of recent studies indicate that these abnormal physiological states have impaired water excretion as a result of both nonosmolar factors ...
[25]
Osmotic and Nonosmotic Regulation of Arginine Vasopressin during ...
Mar 18, 2008 · This hypothesis suggests that nonosmotic stimuli to AVP secretion can occur normally during prolonged endurance exercise.
[26]
Diabetes Insipidus - NIDDK
Diabetes insipidus is usually caused by problems with a hormone called vasopressin that helps your kidneys balance the amount of fluid in your body. Problems ...
[27]
Diabetes Insipidus: Pathogenesis, Diagnosis, and Clinical ...
Feb 23, 2021 · This is primarily caused by acquired factors such as traumatic brain injuries (TBI), infections, loss of blood to the posterior pituitary or ...
[28]
Nephrogenic Diabetes Insipidus (NDI): Clinical, Laboratory and ...
Manifestations include polyuria, polydipsia, hyposthenuria, recurrent episodes of dehydration and fever and growth failure. Most cases are caused by mutations ...<|separator|>
[29]
Transient diabetes insipidus in pregnancy - PMC - PubMed Central
Gestational diabetes insipidus (DI) is a rare complication of pregnancy, estimated to occur in about two to four of every 100 000 pregnancies. The onset of ...
[30]
Syndrome of Inappropriate Antidiuretic Hormone Secretion - NCBI
SIADH is a condition defined by the unsuppressed release of antidiuretic hormone (ADH) from the pituitary gland or nonpituitary sources or its continued action ...
[31]
Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)
Jul 24, 2020 · The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) is a condition characterized by hypotonic and euvolemic hyponatremia along with urinary ...
[32]
Diagnostic Testing for Diabetes Insipidus - Endotext - NCBI Bookshelf
Nov 28, 2022 · This chapter describes the diagnostic steps to be pursued to identify the presence of DI, distinguish the various forms of polyuria-polydipsia disorders.ABSTRACT · DIAGNOSING DIABETES... · DIAGNOSIS OF THE TYPE OF...
[33]
Measuring Oxytocin and Vasopressin: Bioassays, Immunoassays ...
117 measured plasma samples using both a radioimmunoassay and the Enzo ELISA. Radioimmunoassay of extracted samples returned mean levels of 1.1 pg/ml, and ...
[34]
Development and clinical application of a new method for ... - PubMed
A radioimmunoassay has been developed that permits reliable measurements of plasma arginine vasopressin (AVP) at concentrations as low as 0.5 pg/ml in sample ...Missing: ELISA | Show results with:ELISA
[35]
Antidiuretic Hormone (ADH) - Testing.com
Nov 9, 2021 · A water deprivation ADH stimulation test is sometimes used to confirm a diagnosis of diabetes insipidus and to distinguish between the two types ...At a Glance · What is being tested? · Common Questions
[36]
Antidiuretic hormone release associated with increased intracranial ...
May 23, 2018 · Normal ADH values in plasma = 0.2–1.7 pg/ml, Merck Manual Professional Edition (Wians, 2015). Normal plasma osmolality = 275–295 mOsm/kg water, ...
[37]
Diabetes Insipidus Workup: Approach Considerations, Water ...
Apr 4, 2024 · The water deprivation test (ie, the Miller-Moses test), a semiquantitative test to ensure adequate dehydration and maximal stimulation of ADH ...Missing: deficiency | Show results with:deficiency
[38]
Endocrine Testing for the Syndrome of Inappropriate Antidiuretic ...
Dec 22, 2022 · Furthermore, a hypertonic (3%) saline test has been proposed for SIADH (20). However, this test strategy still needs to be validated.ABSTRACT · CLINICAL PRESENTATION... · HYPONATREMIA IN...
[39]
Arginine or Hypertonic Saline–Stimulated Copeptin to Diagnose ...
Nov 15, 2023 · Hypertonic saline–stimulated copeptin has been used to diagnose AVP deficiency with high accuracy but requires close sodium monitoring. Arginine ...Missing: SIADH | Show results with:SIADH
[40]
MR Imaging of Central Diabetes Insipidus: A Pictorial Essay - PMC
MR imaging provides high-resolution images of the pituitary gland, pituitary stalk, and adjacent structures.
[41]
Diabetes insipidus - Diagnosis and treatment - Mayo Clinic
Apr 5, 2023 · Magnetic resonance imaging (MRI). An MRI can look for problems with the pituitary gland or hypothalamus.
[42]
Desmopressin (nasal route) - Side effects & dosage - Mayo Clinic
Jul 1, 2025 · Dosing · Adults and children 13 years of age and older—0.1 to 0.4 milliliter (mL) given as a single dose or divided into 2 or 3 doses per day.
[43]
Desmopressin (oral route) - Side effects & dosage - Mayo Clinic
Jul 1, 2025 · Adults and children 4 years of age and older—At first, 0.05 milligram (mg) 2 times a day. Your doctor may adjust your dose as needed. However, ...
[44]
Oral desmopressin in central diabetes insipidus - PubMed
Patients were discharged from hospital on a preliminary dosage regimen ranging from 100 to 400 mcg three times daily. After an initial adjustment in dosage in ...
[45]
Acute esophageal variceal bleeding: Current strategies and new ...
Terlipressin: Terlipressin is a synthetic analogue of vasopressin with longer activity and fewer side effects. It reduces portal pressure and its effects are ...Ascites And Renal Function · Hemostatic Therapies · Endoscopic Therapy
[46]
Tolvaptan (oral route) - Side effects & dosage - Mayo Clinic
Nov 1, 2025 · Adults—At first, 15 milligrams (mg) once a day. Your doctor will adjust your dose as needed. However, the dose is usually not more than 60 mg ...
[47]
Conivaptan and its role in the treatment of hyponatremia - PMC
Patients received a loading dose of iv conivaptan 20 mg as a 30-minute infusion followed by a continuous iv infusion of conivaptan 20 or 40 mg/day for 4 days.
[48]
Desmopressin Side Effects: Common, Severe, Long Term - Drugs.com
Sep 11, 2025 · Nervous system side effects have included seizures and/or coma as a result of severe water intoxication and hyponatremia. Other nervous system ...
[49]
Tolvaptan Side Effects: Common, Severe, Long Term - Drugs.com
Feb 13, 2025 · The most frequently reported side effects included thirst, dry mouth (up to 13%), asthenia, constipation, pollakiuria or polyuria and hyperglycemia.